4548 On Other Exchanges
4548 is not on other exchanges.

seikagaku corp (4548) Snapshot

Previous Close
Day High
Day Low
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for SEIKAGAKU CORP (4548)

Related News

No related news articles were found.

seikagaku corp (4548) Related Businessweek News

No Related Businessweek News Found

seikagaku corp (4548) Details

Seikagaku Corporation manufactures and sells pharmaceuticals and medical devices primarily related to glycoconjugates in Japan and internationally. The company operates through, Pharmaceuticals and LAL segments. It offers pharmaceuticals and medical devices, including intra-articular injections for improving joint functions under the brands of ARTZ, ARTZ Dispo, SUPARTZ FX, ARTZAL, etc.; ophthalmic surgical aids under the brands OPEGAN, OPEGAN Hi, and SHELLGAN; surgical aids for endoscopic mucosal resection under the brand name of MucoUp; and cross-linked hyaluronate hydrogel for knee osteoarthritis under the brand name of Gel-One. The company also provides bulk products comprising sodium hyaluronate, which is used as a raw material for the manufacturers of pharmaceuticals; and sodium chondroitin sulfate that is used as a raw material in pharmaceuticals, ophthalmic products, and drinks for nutritional fortification. In addition, it develops endotoxin-detecting reagents for use in quality control in the manufacturing process and release test of pharmaceuticals and medical devices, as well as in quality management of fluids for hemodialysis under the Pyrochrome, ENDOSPECY, TOXICOLOR, etc. brands. Further, the company develops and markets oral care products comprising mouthwash under the KINUSUI Spray brand. Additionally, its products under development include SI-6603 that is in Phase III clinical trials for lumbar disc herniation; SI-614, a modified hyaluronate for dry eyes; and SI-613, a formulation for knee osteoarthritis. The company was formerly known as K.K. Seikagaku Kenkyusho and changed its name to Seikagaku Corporation in 1962. Seikagaku Corporation was founded in 1947 and is headquartered in Tokyo, Japan.

663 Employees
Last Reported Date: 06/21/16
Founded in 1947

seikagaku corp (4548) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

seikagaku corp (4548) Key Developments

Seikagaku Corporation and Ferring Pharmaceuticals Enters into Worldwide License Agreement for SI-6603

Seikagaku Corporation and Ferring Pharmaceuticals announced that the companies have entered into an exclusive worldwide license agreement (excluding Japan) for SI-6603 (condoliase), a potential treatment for lumbar disc herniation. The agreement is based on a letter of intent concluded on June 15, 2016. Under the license agreement, Ferring acquires exclusive development and commercialization rights to SI-6603 worldwide, excluding Japan. Seikagaku will receive an upfront payment of $5 million and milestone payments up to a maximum total amount of $90 million over multiple years upon future progress in development and commercialization. SI-6603 is a product Seikagaku has been developing in Japan and the U.S. In the U.S., Seikagaku is conducting two Phase III clinical trials (a pivotal double-blind study and an open-label safety study). Seikagaku intends to accelerate the development of SI-6603 in the U.S. in order to achieve early entry to the U.S. market, where high growth potential is expected.

Seikagaku Corp. Reports Consolidated Earnings Results for the First Quarter Ended June 30, 2016; Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2017; Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2017

Seikagaku Corp. reported consolidated earnings results for the first quarter ended June 30, 2016. For the quarter, net sales were JPY 8,275 million against JPY 7,762 million a year ago. Operating income was JPY 379 million against JPY 883 million a year ago. Ordinary income was JPY 410 million against JPY 1,377 million a year ago. Net income attributable to owners of parent was JPY 287 million against JPY 1,032 million a year ago. Net income per share was JPY 5.06 against JPY 18.18 a year ago. For the second quarter of fiscal year ending March 31, 2017, the company expects to pay a dividend of JPY 13.00 per share compared to JPY 13.00 per share paid a year ago. For the fiscal year ending March 31, 2017, the company expects to pay a dividend of JPY 13.00 per share compared to JPY 13.00 per share paid a year ago. For the fiscal year ending March 31, 2017, on consolidated basis, the company expects net sales of JPY 29,550 million, operating income of JPY 1,000 million, ordinary income of JPY 3,350 million, net income attributable to owners of parent of JPY 3,350 million and net income per share of JPY 45.00.

Seikagaku Corp. to Report Q1, 2017 Results on Jul 28, 2016

Seikagaku Corp. announced that they will report Q1, 2017 results at 3:00 PM, Tokyo Standard Time on Jul 28, 2016


The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

4548 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4548.
View Industry Companies

Industry Analysis


Industry Average

Valuation 4548 Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact SEIKAGAKU CORP, please visit www.seikagaku.co.jp. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.